FORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *